TABLE 2.

HBV core-specific T-cell proliferative responses

Corea	Controlsb				Treated patientsc
	Non-HBV-treated (n = 7)		HCV children (n = 12)	HBV-negative adults (n = 14)	TW0 vs. TW9		TW0 vs. TW28		TW0 vs. TW52
	Yr 0	Yr 1			R (n = 5)	NR (n = 18)	R (n = 5)	NR (n = 5)	R (n = 5)	NR (n = 18)
1 (aa 1-56)	0.92 (0.52-1.25)	0.97 (0.62-1.12)	1.01 (0.68-1.18)	0.99 (0.67-1.30)	0.23	0.05	0.09	0.09	0.01	0.41
2 (aa 49-104)	1.01 (0.56-1.14)	0.99 (0.57-1.24)	0.93 (0.69-1.21)	1.03 (0.54-1.08)	0.56	0.55	0.01	0.15	0.02	0.59
3 (aa 97-152)	1.08 (0.72-1.18)	1.02 (0.69-1.31)	1.11 (0.77-1.23)	0.99 (0.56-1.31)	0.34	0.25	0.02	0.44	0.01	0.21
4 (aa 145-183)	1.10 (0.68-1.35)	1.08 (0.71-1.33)	1.04 (0.74-1.13)	0.98 (0.55-1.15)	0.74	0.82	0.01	0.84	0.01	0.92

^aaa, amino acids.

^bResults are expressed as median and range.

^cBoldface numbers represent significant differences between two treatment time points.